Callio Therapeutics
Callio Therapeutics is a clinical-stage biotech developing first-in-class dual-payload antibody-drug conjugates for HER2-expressing solid tumors, with its lead program CLIO-8221 in Phase I trials.
- Company typePrivate
- Founded2025
- HeadquartersSeattle, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Callio Therapeutics does
Callio Therapeutics, Inc. is a clinical-stage biotechnology company founded in March 2025 that develops next-generation dual-payload antibody-drug conjugates (ADCs) for the treatment of solid tumors. The company's proprietary platform features differentiated payload and linker chemistries enabling targeted co-delivery of two drug classes to tumor cells; its lead asset CLIO-8221 is a first-in-class HER2-targeted ADC combining a topoisomerase 1 (Topo1) inhibitor with an ATR inhibitor, designed to overcome resistance mechanisms common with single-payload ADCs. CLIO-8221 entered a Phase I clinical trial in March 2026 in HER2-expressing solid tumors, with initial sites in Australia and the United States following FDA IND clearance and plans to expand into China pending NMPA review.
The company operates a dual-headquarters structure with its U.S. base in Seattle, Washington and an Asia-Pacific regional headquarters in Singapore. The $187 million Series A financing closed at launch, led by Frazier Life Sciences with participation from a syndicate of life sciences investors, is funding clinical proof-of-concept for CLIO-8221 and a second undisclosed ADC program. Callio is pre-revenue; its revenue model anticipates potential partnerships or direct commercialization following regulatory approval, with near-term value creation dependent on clinical readouts rather than product sales.
The leadership team is composed of operators with prior successful ADC and oncology exits, including CEO Zachary Hornby (formerly of Boundless Bio and Ignyta, which was acquired by Roche for $2 billion), CMO Naomi Hunder and CBO Kevin Hambly (both formerly of ProfoundBio, acquired by Genmab for $1.8 billion in 2024), and scientific co-founders Piers Ingram and Jerome Boyd-Kirkup, who previously co-founded Hummingbird Bioscience. The company employs between 1 and 10 staff per firmographic data and pursues a focused oncology development strategy targeting HER2-positive breast, gastric, and other HER2-expressing solid tumors, including patients who have relapsed on or are refractory to trastuzumab deruxtecan.
Callio Therapeutics firmographics
Firmographics- Name
- Callio Therapeutics
- Legal name
- Callio Therapeutics, Inc.
- Website
- https://calliotx.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Callio Therapeutics is a clinical-stage biotech developing first-in-class dual-payload antibody-drug conjugates for HER2-expressing solid tumors, with its lead program CLIO-8221 in Phase I trials.
- Ownership category
- akta.pro rank
Callio Therapeutics industry classification
Industry- Product category
- Oncology Biopharmaceuticals (ADC Therapeutics)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro industry
- Antibody-Drug Conjugates (ADCs) & Antibody ConjugatesHealthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
Keywords
Where Callio Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Callio Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Development: Pre-revenue clinical-stage biotech company. Revenue potential from drug development through clinical proof-of-concept, with anticipated partnerships or direct commercialization following regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Callio Therapeutics product offering
Product offeringCore offering
Callio Therapeutics is a clinical-stage biopharmaceutical company developing next-generation, multi-payload antibody-drug conjugates (ADCs) featuring differentiated payload and linker technologies for targeted delivery of drug combinations to tumor cells. Its lead program CLIO-8221 is a first-in-class dual-payload HER2-targeted ADC combining a topoisomerase 1 (Topo1) inhibitor and an ATR inhibitor, currently in Phase I clinical trials for HER2-expressing solid tumors. A second undisclosed ADC program is also being advanced through clinical proof-of-concept.
Product overview
Callio Therapeutics is developing a next-generation multi-payload antibody-drug conjugate (ADC) platform and pipeline. The company's lead program is CLIO-8221, a first-in-class dual-payload HER2-targeted ADC combining topoisomerase 1 (Topo1) and ATR inhibitors to overcome resistance mechanisms common with single-payload ADCs. The company also has a second undisclosed ADC program. The platform technology enables targeted delivery of drug combinations to tumor cells to maximize therapeutic benefit for cancer patients.
Differentiator
Problem solved
Functional benefit
Products and services
- CLIO-8221 A first-in-class dual-payload antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors. It is engineered for targeted co-delivery of a topoisomerase 1 (Topo1) inhibitor and an ATR inhibitor to overcome resistance mechanisms common with single-payload ADCs, including failure after trastuzumab deruxtecan. Currently in Phase I clinical trials in Australia and the U.S.
- Second Undisclosed ADC Program A second ADC program in Callio's pipeline, undisclosed as to target or payload, being advanced through clinical proof-of-concept alongside CLIO-8221 using Series A funding.
Quantifiable outcome
- Wide therapeutic window with strong durable activity demonstrated in preclinical studies for CLIO-8221
Companies that use Callio Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Callio Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Callio Therapeutics partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights5 records
Callio Therapeutics competitors and assessment
Company assessmentDirect peers
- ProfoundBio: Clinical-stage ADC developer acquired by Genmab for $1.8B in 2024. ProfoundBio developed HER2 and other ADCs with differentiated payload and linker technologies — closely comparable to Callio's platform. Several Callio executives (CMO, CBO) and board members came directly from ProfoundBio.
- Mersana Therapeutics: Clinical-stage ADC company developing next-generation antibody-drug conjugates using proprietary platforms (Dolasynthen, Immunosynthen). Competes directly with Callio in the differentiated-payload ADC space across HER2 and other oncology targets.
- Pyxis Oncology: Clinical-stage ADC and immuno-oncology company developing antibody-drug conjugates with novel payloads and linkers. Directly comparable as a platform ADC company pursuing differentiated payload strategies in oncology.
Emerging players
- Tubulis: European biotech developing next-generation ADCs with differentiated conjugation and payload technologies. Comparable as a platform-focused ADC innovator with multiple preclinical and early clinical programs, similar in scale and stage to Callio.
- Bolt Biotherapeutics: Clinical-stage oncology company developing immune-stimulating antibody conjugates (ISACs), a distinct but adjacent ADC modality. Comparable as a novel-payload ADC platform pursuing differentiated mechanisms from conventional cytotoxic ADCs.
- Heidelberg Pharma: Germany-based ADC company developing ADCs using the cytotoxic payload amanitin. Comparable as a platform ADC company using differentiated payloads to overcome resistance — directly relevant to Callio's dual-payload thesis.
- Byondis: Clinical-stage ADC developer with proprietary linker-payload technology (HydraSpace/DuoBody). Comparable as a differentiated ADC platform company with HER2-targeted programs in clinical development.
Broad incumbents
- Daiichi Sankyo: Japanese pharmaceutical company that developed Enhertu (trastuzumab deruxtecan), the dominant HER2 ADC and standard of care in HER2-positive tumors. Sets the competitive benchmark Callio must beat in HER2-expressing tumors.
- Pfizer (Seagen): Pfizer acquired Seagen in 2023 for $43B, gaining Adcetris, Padcev, and Tivdak — multiple approved ADCs. Seagen's CMC and clinical ADC infrastructure established the template that newer ADC platforms like Callio's are now challenging.
- AbbVie (ImmunoGen): AbbVie acquired ImmunoGen in 2024, gaining Elahere and the ADC platform that pioneered the mirvetuximab soravtansine approval. Comparable as a broad incumbent with a full ADC development platform and approved products in oncology.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Callio Therapeutics social profiles
Digital presenceCallio Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Callio Therapeutics leadership team
Management profileNumber of profiles
Profiles8 records
Callio Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Callio Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Callio Therapeutics
What does Callio Therapeutics do?
Callio Therapeutics is a clinical-stage biopharmaceutical company developing next-generation, multi-payload antibody-drug conjugates (ADCs) featuring differentiated payload and linker technologies for targeted delivery of drug combinations to tumor cells. Its lead program CLIO-8221 is a first-in-class dual-payload HER2-targeted ADC combining a topoisomerase 1 (Topo1) inhibitor and an ATR inhibitor, currently in Phase I clinical trials for HER2-expressing solid tumors. A second undisclosed ADC program is also being advanced through clinical proof-of-concept.
Is Callio Therapeutics a public or private company?
Callio Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Callio Therapeutics founded?
Callio Therapeutics was founded in 2025. It employs 11 to 50 people.
Where is Callio Therapeutics based?
Callio Therapeutics is headquartered in Seattle, United States, in the North America region.
How does Callio Therapeutics make money?
One revenue line is on record: pharmaceutical Development.
Who are Callio Therapeutics's main competitors?
Direct peers on record are ProfoundBio, Mersana Therapeutics and Pyxis Oncology. Emerging players are Tubulis, Bolt Biotherapeutics, Heidelberg Pharma and Byondis. Broad incumbents are Daiichi Sankyo, Pfizer (Seagen) and AbbVie (ImmunoGen).
Does Callio Therapeutics have an API?
No public API is recorded for Callio Therapeutics.
What industry is Callio Therapeutics in?
Callio Therapeutics's product category is Oncology Biopharmaceuticals (ADC Therapeutics). Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2834.